Browse by category

Apnimed has announced positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of obstructive sleep apnoea (OSA). The study demonstrated that sulthiame significantly improved important OSA metrics in adults with moderate to severe OSA. Sulthiame has a different mechanism of action from Apnimed's lead programme, AD109, with the potential to address other aspects of the pathophysiology of

Health care experts urge increased awareness of obstructive sleep apnoea among people with cardiovascular disease or risk factors such as...